One2Treat is a forward-thinking partner for biopharmaceutical companies, dedicated to delivering transformative insights in clinical trial design, analysis, and market access evaluations to support holistic treatment decisions. One2Treat was founded in July 2023 after four years of advanced Research and Software Development incubation within IDDI Group.
Driven by a commitment to patient-centricity, One2Treat leverages modern statistical methodologies and advanced software solutions, ushering in a new era of personalized healthcare.
Through its innovative solutions, One2Treat aims to empower clinicians to provide patients with personalized care that is tailored to their treatment preferences and unique needs.
One2Treat’s mission is to develop methods and advanced software that enable a holistic evaluation of treatment effects by integrating all key patient-relevant outcomes into a single comprehensive assessment of the Net Treatment Benefit.
One2Treat applies state-of-the-art computing to the large volumes of patient data collected in clinical trials and supportive real-world evidence. This allows us to undertake more clinically meaningful statistical analysis of treatment effects, incorporating all outcomes that matter to patients. As a result, our approach significantly reduces trial sample sizes and expedites innovative treatments time to market.
